{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-23-000036","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.365391+00:00","generated_at":"2026-06-11T21:32:03.242149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance","bullets":["Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.","Xywav sales $326.6M (+39% YoY); Epidiolex $202.2M (+15%); Rylaze $101.7M (+39%).","Raises FY2023 guidance: revenue $3.725-$3.875B; non-GAAP adjusted EPS raised to $18.15-$19.00 from $16.90-$17.85.","Repurchased $100M in shares under $1.5B program; $336M remaining as of June 30, 2023.","Combined oxybate revenue (incl. AG royalties) $491.8M (-2% YoY); Xyrem down 41% to $159.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-23-000036","json":"https://secwatch.observer/filing/0001232524-23-000036.json","markdown":"https://secwatch.observer/filing/0001232524-23-000036.md","text":"https://secwatch.observer/filing/0001232524-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/0001232524-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/jazz-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:32:03.242149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fb33df033d4f549e47f128255bc88e19dc61a99","claim":"Jazz Pharmaceuticals plc updated its the second quarter of 2023 guidance (raised).","evidence_excerpt":"On August 9, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/0001232524-23-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}